Brief: Valeant Announces Licensing Agreement With Kaken Pharma For Psoriasis Treatment

KAKEN PHARMACEUTICAL

27/02/2018 23:45

Feb 27 (Reuters) - Valeant  VRX.TO : 
    * ANNOUNCES LICENSING AGREEMENT WITH KAKEN PHARMACEUTICAL 
CO., 
LTD. TO DEVELOP AND COMMERCIALIZE NEW CHEMICAL ENTITY FOR 
PSORIASIS 
    * UNDER TERMS OF LICENSING AGREEMENT, KAKEN GRANTED TO CO 
EXCLUSIVE LICENSE TO DEVELOP AND COMMERCIALIZE TOPICAL PRODUCTS 
CONTAINING KP-470 
    * WILL HAVE RIGHTS TO DEVELOP AND COMMERCIALIZE PRODUCTS 
WITH 
KP-470 IN UNITED STATES, CANADA, AND WESTERN AND EASTERN EUROPE 
    * KAKEN TO RECEIVE UPFRONT CASH PAYMENT AND HAS POTENTIAL 
TO 
RECEIVE CERTAIN DEVELOPMENT-BASED MILESTONE PAYMENTS 
    * ADDITIONALLY, KAKEN WILL RECEIVE ROYALTIES ON VALEANT'S 
NET 
SALES OF PRODUCTS 
 
Source text for Eikon:  ID:nPn8kCHZ6a  
Further company coverage:  VRX.TO  
 
 ((Reuters.Briefs@thomsonreuters.com;))